Polymyositis vs Dermatomyositis: How to Tell Them Apart
Polymyositis and dermatomyositis are both idiopathic inflammatory myopathies that produce symmetric proximal muscle weakness with markedly elevated muscle enzymes. The core axis that separates them is the skin: dermatomyositis pairs the myopathy with pathognomonic cutaneous findings, while polymyositis has none. Their immunopathology and muscle biopsy patterns also diverge, and dermatomyositis carries a well-established malignancy association that polymyositis largely lacks.
How to tell them apart
| Feature | Polymyositis | Dermatomyositis |
|---|---|---|
| Skin findings | None — myopathy without cutaneous involvement | Characteristic skin findings such as heliotrope rash, Gottron papules/sign, V-sign, shawl sign, mechanic's hands, and nail fold capillary changes |
| Pathognomonic cutaneous signs | Absent | Heliotrope rash (violaceous discoloration of the upper eyelids) and Gottron papules (violaceous papules over the MCP/PIP/DIP joints) are pathognomonic |
| Immunopathogenesis | CD8+ T-cell–mediated attack directly on non-necrotic muscle fibers (cell-mediated, endomysial) | Complement-mediated microangiopathy; immune complexes damage capillaries in muscle and skin, with B-cell and CD4+ T-cell involvement (humoral, perivascular) |
| Muscle biopsy | Endomysial inflammation with CD8+ T cells surrounding and invading non-necrotic fibers; no perifascicular atrophy | Perifascicular atrophy (highly characteristic), perivascular and perimysial inflammation, and complement (MAC) deposition in capillaries |
| Malignancy association | Weak and debated — a clearly, consistently elevated cancer risk has not been reliably demonstrated, and any increase is far less than in dermatomyositis | Strong, well-established association with underlying malignancy (ovarian, lung, pancreatic, GI); cancer may precede, accompany, or follow the myopathy by up to 3 years |
| Malignancy-associated antibodies | Not linked to the myositis-specific malignancy antibodies; anti-SRP may mark a necrotizing myopathy phenotype | Anti-TIF1-gamma and anti-NXP2 signal strong malignancy risk; anti-Mi-2 is classically associated with dermatomyositis skin disease |
| Amyopathic form | Not described — muscle involvement defines the disease | Amyopathic dermatomyositis can present with characteristic skin findings and no muscle involvement (myopathy may develop later) |
The reasoning
Anchor on the skin. Both diseases produce symmetric proximal weakness with high CK, preserved reflexes, and intact sensation — a myopathic pattern. The presence of pathognomonic cutaneous signs (heliotrope rash, Gottron papules) immediately establishes dermatomyositis; their complete absence in a proximal inflammatory myopathy points to polymyositis. When the clinical picture is ambiguous, muscle biopsy arbitrates: perifascicular atrophy defines dermatomyositis, whereas endomysial CD8+ T cells invading intact fibers defines polymyositis. In any adult with dermatomyositis, pursue malignancy screening because of the strong cancer association — a link that is much less robust and remains debated in polymyositis.
Key tests
- Muscle enzymes (CK, AST, aldolase): markedly elevated in both — confirms active muscle disease but does not distinguish them
- Muscle biopsy (gold standard): polymyositis shows endomysial inflammation with CD8+ T cells invading non-necrotic fibers and no perifascicular atrophy; dermatomyositis shows perifascicular atrophy with perivascular/perimysial inflammation and capillary complement deposition
- Myositis-specific antibodies: anti-TIF1-gamma, anti-NXP2, and anti-Mi-2 point to dermatomyositis (the first two flag malignancy risk), whereas antisynthetase antibodies such as anti-Jo-1 mark antisynthetase syndrome and can occur in either disease
- Skin examination and malignancy workup: heliotrope rash and Gottron papules confirm dermatomyositis; adults with dermatomyositis require occult malignancy screening (age-appropriate screening, CT chest/abdomen/pelvis, CA-125 and transvaginal ultrasound in women), repeated over the first years since cancer may manifest within 3 years
What they share
- Symmetric proximal muscle weakness (difficulty climbing stairs, rising from a chair, raising the arms)
- Markedly elevated CK reflecting active muscle disease
- Preserved reflexes and intact sensation (a myopathic, not neuropathic, pattern)
- Autoimmune inflammatory attack on skeletal muscle
- Insidious onset over weeks to months
- Antisynthetase syndrome (anti-Jo-1 and other antisynthetase antibodies) with interstitial lung disease, mechanic's hands, Raynaud phenomenon, and arthritis — occurs in both, classically described in polymyositis
- Responsiveness to corticosteroids and other immunosuppressive therapy
Pitfalls
- Forgetting to screen adult dermatomyositis patients for occult malignancy — the cancer may precede, accompany, or follow the myopathy by up to 3 years, so a single negative screen is not enough.
- Overstating the polymyositis–cancer link: the malignancy association in polymyositis is weak and disputed, and it should not be treated as equivalent to the robust association seen in dermatomyositis.
- Treating anti-Jo-1 or antisynthetase syndrome as dermatomyositis-specific — these antibodies (with mechanic's hands and interstitial lung disease) occur in both diseases and are classically described in polymyositis.
- Labeling a treatment-resistant 'polymyositis' as steroid failure without reconsidering inclusion body myositis, which affects older patients, involves distal muscles, and does not respond to steroids.
- Assuming the CK level or a myopathic pattern alone can separate the two — enzymes and weakness distribution are shared; only the skin findings and biopsy pattern reliably discriminate.
- Missing amyopathic dermatomyositis: characteristic skin findings can occur without muscle weakness, and myopathy may only develop later.
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.